Neothetics (NEOT) Reports Q4 Loss of $0.14/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results
March 23, 2017 8:00 AM EDTSAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ: NEOT) today provided a business update and reported financial results for the fourth quarter 2016.
We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to expect top-line data in June 2017, said Mr. Jeffrey M. Nugent, a member of Neothetics Operating Committee and Board of Directors. We remain excited about the submental fat reduction market and continue to believe LIPO-202 will have significant impact on this market. The American Society of Dermatologic Surgeons (ASDS) 2016... More
